Oncology & Cancer 2022 | London | United Kingdom | Allied Conferences | Meetings

Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academies Conferences

Theme

Novel research and advancement in the field of Oncology

- Oncology & Cancer 2022

Welcome Message

We cordially invite you all to the 15^th Global summit on Oncology and Cancer and to participate in this global gathering of researchers, oncologists, healthcare professionals, young researchers, students and delegates.

The theme of our conference is ‘Novel research and advancement in the field of Oncology’. It is slated on March 18-19, 2022 in London, UK.

Oncology 2022provides an opportunity to network with well-known people from around the world and to advance one's knowledge in the field of oncology. Keynote lectures, special sessions, poster presentations, plenary speeches, and more are all part of the conference agenda. All research scholars, academic researchers, doctors, clinical healthcare specialists and young researchers are invited to attend this conference.

It gives you a unique opportunity to network with eminent doctors, professors, researchers, scientists, and CEOs from all over the world, as well as share data with the brightest minds in the fields of Cancer Biology and Oncology, Cell and Gene Therapy, Medical and Radiation Oncology, Metastasis and Drug Resistance, Lung Cancer, Breast Cancer, Clinical Oncology, Chemotherapy, and other related fields.

Why to attend our conference?

We extend you an opportunity to present your work in front of notable experts in the industry.

The opportunity to hear from some of the world's most recognized scientists and lecturers all in one place.

In order to obtain significant CME credits.

Access to the world's leading industries in the subject of oncology.

Your study will be recognized on a global scale.

Meet and greet professionals from all over the globe.

Target Audience:

Oncology Societies

Clinical Researchers

Leading world Doctors

Health Professional

Radiation Therapist

Young researchers

Students and delegates

Drug Manufacturing Companies

Exhibitors

IMPORTANT LINKS:

Submit abstracthttps://oncology-summit.alliedacademies.com/abstract-submission

Contact: [email protected]

Market Analysis

EUROPE:Canceraccounts for20%of deathswithin theEuropean Region.
Europe has around one-quarter ofthe worldwidetotal ofcancercases with some3.7 million new patientsp.a.

USA:In 2016,there have beenassociatecalculable15.5 millioncancersurvivorswithin theU.S.The quantityofcancersurvivorsis predictedto extendto 20.3 million by 2026.
Estimated national expenditures forcancercarewithin theU.S in 2017 were $147.3 billion.
The most recentCancerStatistics Review,freeinApr2018, shows thatcancerdeath rates in USA isminimizedby:

1.8%p.a.among men from 2006 to 2015.

1.4%p.a.amonggirlsfrom 2006 to 2015.

1.4%p.a.amongyoungstersages 0–19 from 2011 to 2015

ASIA:Asia hasnearly half ofcancerincidence rate of North America (152.2 cases/100,000 person-years versus 315.6 cases/100,000 person-years). However, thequantitative relationofcancerdeaths tothe amountof recentcancercases in 2012 washigher in Asia (0.66) than in North America (0.33).Republic of Indiaalone accounts fortwenty seventhof worldcervicalcancerdeaths,which canflow fromto theinconvenienceof screening.

Smoking and Tobacco:Smoking, the mainexplanation forcarcinoma, contributes to80%and90%ofcarcinomadeaths ingirlsand men,severally. Men whosmokeare 23 times likely to developcarcinoma.Girlsarethirteentimeslikely to develop, compared tone'ersmokers. In Europe, smoking causesnearly82%ofrespiratory organcancers.

Diet and Physical Activity:Severalstudies havechecked outthe chancethat specific dietarypartsornutrientseitherwill increaseor decreases in cancer risk. Studies ofcancer cellswithin thelaboratory and of animal models havetypicallyprovidedproofthat isolated compoundscould also becarcinogenic(or havemalignanttumouractivity).Aiming tostay at a healthy weightis vitalto cut backthe dangerofcancer.To cut backcancer risk,the general publicought is tokeeptheir BMIs belowtwenty-five.Besides, some of the most important things you can do to helpreduce yourcancerrisk are:

Stay at a healthy weight throughout life.

Be physically active on a daily basis.

Make healthy food decisions with a spot light on plant-based foods.

Sun and Other Types of Radiation:Radiation can causecancerin most parts of the body and at any age, although radiation-induced solidtumoursusually take 10–15 years, and can take upto 40 years, to become clinically manifest, andradiation-induced leukaemia typically require 2–10 years to appear.

Viruses and Other Infections:In the fast developing world, infections such asHelicobacter pylori,hepatitis B,hepatitis C,human papillomavirus infection,Epstein–Barr virusandhuman immunodeficiency virus(HIV) accounts for 15% of cancer.

Oncology Associations:

American Society ofClinical Oncology- ASCO

CommunityOncologyAlliance -COA

Society ofSurgical Oncology-SSO

American Society of Therapeutic Radiology andOncology-ASTRO

American Society of Blood and Marrow Transplantation - ASBMT

American Society of Haematology- ASH

American Association of Cancer Research -AACR

American Cancer Society-ACI

National Cancer Institute-NCI

National Comprehensive Cancer Network-NCCN

Speciality Organisations:

The Society ofGynaecologic Oncology

American Society of Breast Surgeons

Society forHaematologyandStem Cells

The Connective TissueOncologySociety

MusculoskeletalTumourSociety

American Head and Neck Society

Society for Melanoma Research

KidneyCancerAssociation

Society ofUrologic Oncology

Society of Interventional Radiology

Association forCancer Surgery

Pediatric RadiationOncologySociety

American College of RadiationOncology

Children’sOncologyGroup

Society forIntegrative Oncology

American Academy of Hospice and Palliative Medicine

Society for Immunotherapy of Cancer

American PsychosocialOncologySociety

American Society ofPreventive Oncology

Drug and Pharma – Analysis:

The market foroncologymedication is booming, aidingthepharmaceuticaltradegrowth. Theoncologydrug market iscalculableto benearlyninety fourbillion USD. Most ofthe highestpharmaceuticalfirmsareeitherpresentlymanufacturemedicinaldrugsor haveoncology medicationsin their R&D pipelines.

Oncology Pharmaceutical Companies

Roche

Bristol – Myers Squibb

Novartis

Pfizer

Celgene

Johnson & Johnson

Astra Zeneca

Abbvie

Lilly

Merck

Past Conference Report

We would like to express a great appreciation to all the plenary speakers and participants joined this international network and visited London, to make their deposit by their high quality presentations, exciting and interesting discussions at the unique atmosphere of this fruitful scientific gathering.

AAChosted14th GlobalSummit on Oncology and CancerduringMarch 18-19, 2019atLondon, UKbased on the theme“Ray of Hope on Bridging Cancer Research and Treatment”.

Oncology2019 was marked with multiple sessions, keynote presentations and panel discussions. We received copious involvement and response from young and brilliant researchers,business delegates and talented communities who made this Conference as one of the most successful and productive events in 2019 from AAC.

The meeting was carried out through different sessions, in which the discussions were held on the following major scientific topics:

Cancer Biology and Oncology

Oncology Causes and Diagnosis

Oncology and Stem cell Treatment

Medical and Radiation Oncology

Cell and Gene Therapy

Immunotherapy and Immuno-oncology

Carcinogenesis and Cancer Mutagenesis

Gynaecologic Oncology

Lung Cancer

Breast Cancer

Conference carried out by various scientific-sessions and plenary lectures in which the following Speakers were highlighted asKeynote speakers:

Stanley P L Leong | California Pacific Medical Center and Research Institute | USA

Raghu Pandurangi | Sci-Engi-Medco Solutions | USA

Stefan Glueck | Celgene Corporation | USA

Raghavan Rajagopalan | Daya Drug Discoveries | USA

Claude Prigent | Université de Rennes | France

Jan Jacques Michiels | Goodheart Institute | The Netherlands

Elena Drozdova | Samara State Medical University | Russia

Kazuko Tatsumura | Gaia Holistic Health | USA

Bhakos A Tannous | Massachusetts General Hospital | USA

George E Chen | The Chinese University of Hong Kong | China

George Vasmatzis | Mayo Clinic | USA

AAC has taken the privilege of felicitating the Organizing Committee, Keynote Speakers and all the speakers who supported for the grand success of this event. We would like to congratulate the awardees for their outstanding performance in the field of Oncology and Cancer and express our gratitude to all the attendees who put their efforts in presentations and sincerely wishes them success in future endeavours.

Following the success of the Oncology 2019 Conference, we are excited to announce the commencement of the15th GlobalSummit on Oncology and Cancer.

Bookmark your dates: We hope to see you atOncology 2022 in London, UK during March 18-19, 2022

PROCEEDING OF ONCOLOGY CONFERENCES

Oncology 2019 Proceedings athttps://www.alliedacademies.org/conference-abstracts/oncology-cancer-therapy-2019-proceedings.html

Session / Tracks

SessiononCancer BiologyandOncology

The body may usecelldivisionas a conventional means of growth and repair. When there is noneed for more female offspring cells, healthy cells cease proliferating, butcancer cells continue to divide.Cancercellsdivide uncontrollably, producing solid tumours or infiltrating thebloodstream with aberrant cells. These alterations, as well as the molecularnetworks that control cell proliferation, differentiation, and death, arestudied in cancer biology. Medical specialisation refers to the study ofvarious types of cancer.

Session onOncologyCauses,Diagnosis and Treatment

Changes (mutations) inthe polymer among cells causescancer. Cancer'ssigns and symptoms vary depending on which region of the body is afflicted. Todiagnose cancer, doctors look at the symptoms and perform a variety ofdifferent tests. Let's look at the current causes anddiagnosticprocedures for cancer andtumoursthroughoutthis session.

SessiononPreventiveOncology

Between 30 and 50 per cent of all cancer cases are avoidable at the unit level. Interference isthe most effective long-term method forcancermanagement. During this session, we're going to discuss the odds ofpreventing cancer, as well as the stages and tactics involved in doing so!

SessiononRadiationOncology

Radiation oncology isan emerging treatment strategy in cancer cure that employsChemotherapy,Immunotherapy,andHormonalTherapyto treat cancer in an effective manner. This workshop will lookinto an emerging cancer therapy approach.

SessiononSurgicalOncology

Surgicaloncologyis a type of cancer treatment that involves surgery to detect,stage, and treat cancer. The kind, size, location, grade, and stage of thetumour,as well as concerns related to the patient's health, such as age, fitness, andother medical conditions determine whether a patient is a candidate forsurgery.

SessiononRadiationTherapy

Radiationtherapyto eliminate harmful cells has become a common diagnosis method fora variety of cancers. To cure cancer, it usesX-rays,gammarays,electronbeams, orprotons.Adjuvant radiation,palliative radiotherapy,andcurativeradiotherapyare the three types of radiotherapy. Early detection, the sizeof the tumour, and the histological makeup of cancer all play a role in itsprognosis. Gamma Knife surgery, Three-Dimensional Conformal Radiation Therapy,Triggered imaging radiosurgery, Brachytherapy, External Beam RadiationTreatment, Total Body Irradiation, Total Skin Irradiation, Stereotactic BodyRadiation Therapy and others are examples of radiation therapy techniques. Thelatest developments in radiation therapy, as well as any novel methods thathave become accessible, can be discussed.

SessiononCancerChemotherapy

Chemotherapyis a type of cancer treatment that involves the administration of one or moreanti-cancer medications as part of a comprehensive treatment plan. Chemotherapycan also be given with a curative intent, or with the goal of extending life orreducing symptoms. This seminar will look at how to improve treatmenteffectiveness while reducing adverse effects.

SessiononMelanomaand Carcinoma

Melanomais a dangerous type of skin cancer that starts in cells calledmelanocytes.Melanoma is far more hazardous than carcinoma because it can quickly spread toother organs if not treated early, whereascarcinomabegins in cells that make up the skin or tissue lining organs like the liver orkidneys.

SessiononCarcinogenesis&CancerMutagenesis

Carcinogenesisoccurs when normal cells are turned into cancer cells, whilemutagenesisoccurs when genetic information is changed in a natural or artificial fashion,and it can result in a variety of disorders, including cancer. As a result,this session looks into the possibility of mutagenesis being reduced.

SessiononGynaecologicOncology

It is estimated that98,000 women will be diagnosed with gynecologic cancer this year, with only30,000 dying as a result of the illness. Cancers of thefemalereproductive system, such as sex gland cancer, female internal reproductiveorgan cancer, canal cancer, cervical cancer, and others, are investigated inGynecologicmedicine.

SessiononLungCancer

The overall 5-yearsurvival rate for both limited and extended stage small celllungcanceris only about 6% and the average life expectancy for extensivestage without treatment is 2 to 4 months and 6 to 12 months with treatment. Asa result, this workshop will focus on new lung cancer prevention and treatmentstrategies.

Session onBreast Cancer

Breastcanceris the most common invasive cancer in women, and it is also thesecond greatest cause of cancer death in women. As you become older, yourchances of developing carcinoma increase. The chance of having cancer in thenext decade is 0.06 per cent at twenty years. By the age of seventy, thepercentage had risen to 3.84 per cent. As a result, this session can focus onenhancingsurvivability.

SessiononMetastasisandDrugResistance

Cancer cells break awayfrom their original site of formation, migrate via the blood or lymph system,and establish new tumors in distant parts of the body duringmetastasis.Due to drug resistance,chemotherapyfails to treat the majority of cancer patients with advanced disease,particularly those with the most common kinds of solid tumours. As a result,this session focuses onmetastasisrestrictionand breakage ofdrugresistanceto treat cancer.

SessiononDrug Development inOncology

In 2018, theUS Foodand Drug Administration (FDA)approved or added additional indications to47 oncology medications or biologics, while the FDA has already approved 20oncology drugs or biologics in 2019. The drug-development process, which couldlead to approval, is lengthy and involves numerous procedures to guarantee thatthe medication is both safe and effective. We will make a greater contributionto the advancement of this session.

SessiononOncology:Lifestyleand Nutrition

Not only for cancertreatment, but for everyone's health, a healthy lifestyle and proper diet areessential. The degree of cancer risk is determined by one'slifestyleand nutritionchoices. As a result, this class focuses on how to live ahealthy lifestyle!

Session onClinicalTrialsinOncology

Even though there areclinical,medicinal,andsurgicalways for properly treating cancer patients, many new clinical trials are beingconducted in the development of novel therapeutic approaches to treat cancermore effectively and efficiently. As a result, innovative cancer treatmentprocedures can be brought to the world's attention through this session.

Session onOncologyNursing&PalliativeCare

Palliativecareis a type of patient-centred, family-centered care that aims toimprove quality of life by reducing suffering. Medical specialty nurses have theskills necessary to provide high-quality care, and they are well-positioned tohelp reshape palliative care for cancer patients.

SessiononOncologyCaseReports

The investigation ofcancer and tumors, such as bar, identification, and treatment information, isreferred to asoncologyand cancer case reports. This case reports aid in the gathering of informationabout diseases and the development of remedies as a result.

Session onCancerstruggles during COVID-19

People who have had cancertreatment are more likely to have severeCOVID-19 disease.Chemotherapy, radiation, and the medications they were given during treatmentmay have weakened their immune systems, making them more susceptible to thecorona virus.

Organizing committee members

David H Nguyen

Chair

Stanford University, Environmental and Medical Fallout Task Force, Computational Biology, Stanford University Medical Center, USA

Akbari Mohammad Esmail

Shahid Beheshti University of Medical Sciences, Head of Cancer Research Center, Surgical Oncology, Iran

Stephen J Beebe

Research Professor

Old Dominion University, USA

Dimitrios H. Roukos

School of Medicine

Ioannina University, Greece

Prof. Dr. Alireza Heidari

Oklahoma Center for Neuroscience, Oklahoma Center for Neuroscience

USA

Stefan Glueck

Vice President

Celgene Corporation, USA

Jan Jacques Michiels

Founder, BloodCoagulation and Vascular Medicine

Goodheart Institute & Foundation in Nature Medicine & Health, The Netherlands

Caspar Haule

General Surgeon/Head of Breast Unit

Muhimbili National Hospital, Tanzania

Dr Inés Llamas-Ramos

Executive Editor, Physiotherapy

University of Salamanca, Spain

Dr Sergey Suchkov

Director, Dept for Translational Medicine

Sechenov University, Russia

To Collaborate Scientific Professionals around the World

Conference Date	March 18-19, 2022
Poster Oppurtunity	Available
e-Poster Oppurtunity	Available

Testimonials

Rajendra D. Badgaiyan

Southern University, USA

I have been working in oncology for several years, but attending the cancer conference gave me new insights and perspectives on how we can improve patient care. The speakers were all experts in their fields and provided valuable information on top